Lyell Immunopharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
DEF: Lyell Immunopharma Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing
Lyell Immunopharma is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and potentially improve stock marketability.
NASDAQ
Lyell Immunopharma, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
Lyell Immunopharma's 2024 Annual Meeting of Stockholders will be held virtually on June 14, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and conduct an advisory vote on executive compensation.